Laboratorios Farmaceuticos ROVI (ROVI) - Total Liabilities
Based on the latest financial reports, Laboratorios Farmaceuticos ROVI (ROVI) has total liabilities worth €289.27 Million EUR (≈ $338.18 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore ROVI long-term investment intensity to see how much of total assets are deployed in long-term investments.
Laboratorios Farmaceuticos ROVI - Total Liabilities Trend (2003–2024)
This chart illustrates how Laboratorios Farmaceuticos ROVI's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of Laboratorios Farmaceuticos ROVI.
Laboratorios Farmaceuticos ROVI Competitors by Total Liabilities
The table below lists competitors of Laboratorios Farmaceuticos ROVI ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Canadian Apartment Properties Real Estate Investment Trust
TO:CAR-UN
|
Canada | CA$6.41 Billion |
|
Constellium Nv
NYSE:CSTM
|
USA | $4.82 Billion |
|
First Capital Real Estate Investment Trust
TO:FCR-UN
|
Canada | CA$4.35 Billion |
|
Nuscale Power Corp
NYSE:SMR
|
USA | $35.54 Million |
|
CMB.TECH NV
BR:CMBT
|
Belgium | €5.82 Billion |
|
Quálitas Controladora S.A.B. de C.V.
MX:Q
|
Mexico | MX$96.22 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥2.82 Billion |
|
Henan Huanghe Whirlwind Co Ltd
SHG:600172
|
China | CN¥6.74 Billion |
Liability Composition Analysis (2003–2024)
This chart breaks down Laboratorios Farmaceuticos ROVI's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Laboratorios Farmaceuticos ROVI net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.47 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.31 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Laboratorios Farmaceuticos ROVI's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Laboratorios Farmaceuticos ROVI (2003–2024)
The table below shows the annual total liabilities of Laboratorios Farmaceuticos ROVI from 2003 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €250.48 Million ≈ $292.84 Million |
-2.30% |
| 2023-12-31 | €256.39 Million ≈ $299.75 Million |
-28.25% |
| 2022-12-31 | €357.32 Million ≈ $417.75 Million |
+36.54% |
| 2021-12-31 | €261.70 Million ≈ $305.95 Million |
+30.37% |
| 2020-12-31 | €200.74 Million ≈ $234.68 Million |
+6.31% |
| 2019-12-31 | €188.82 Million ≈ $220.76 Million |
+63.87% |
| 2018-12-31 | €115.23 Million ≈ $134.71 Million |
+8.00% |
| 2017-12-31 | €106.69 Million ≈ $124.74 Million |
+2.16% |
| 2016-12-31 | €104.44 Million ≈ $122.10 Million |
+5.43% |
| 2015-12-31 | €99.06 Million ≈ $115.81 Million |
-3.68% |
| 2014-12-31 | €102.85 Million ≈ $120.24 Million |
+12.45% |
| 2013-12-31 | €91.46 Million ≈ $106.93 Million |
-4.65% |
| 2012-12-31 | €95.92 Million ≈ $112.14 Million |
-15.93% |
| 2011-12-31 | €114.09 Million ≈ $133.38 Million |
+4.90% |
| 2010-12-31 | €108.75 Million ≈ $127.14 Million |
+15.18% |
| 2009-12-31 | €94.42 Million ≈ $110.39 Million |
+30.94% |
| 2008-12-31 | €72.11 Million ≈ $84.30 Million |
+19.71% |
| 2007-12-31 | €60.23 Million ≈ $70.42 Million |
+19.92% |
| 2006-12-31 | €50.23 Million ≈ $58.72 Million |
-100.00% |
| 2005-12-31 | €3.35 Trillion ≈ $3.92 Trillion |
+42431.24% |
| 2004-12-31 | €7.88 Billion ≈ $9.21 Billion |
+25477.80% |
| 2003-12-31 | €30.80 Million ≈ $36.00 Million |
-- |
About Laboratorios Farmaceuticos ROVI
Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Trypti… Read more